



Activation of metabolite receptor GPR91 promotes platelet aggregation and transcellular biosynthesis of leukotriene C₄

Tang, Xiao; Fuchs, David; Tan, Shuai; Trauelsen, Mette; Schwartz, Thue W.; Wheelock, Craig E.; Li, Nailin; Haeggstrom, Jesper Z.

Published in:

Journal of Thrombosis and Haemostasis

DOI:

[10.1111/jth.14734](https://doi.org/10.1111/jth.14734)

Publication date:

2020

Document version

Publisher's PDF, also known as Version of record

Document license:


[CC BY-NC-ND](https://creativecommons.org/licenses/by-nc-nd/4.0/)

Citation for published version (APA):

Tang, X., Fuchs, D., Tan, S., Trauelsen, M., Schwartz, T. W., Wheelock, C. E., ... Haeggstrom, J. Z. (2020). Activation of metabolite receptor GPR91 promotes platelet aggregation and transcellular biosynthesis of leukotriene C₄. *Journal of Thrombosis and Haemostasis*, 18(4), 976-984. <https://doi.org/10.1111/jth.14734>

BRIEF REPORT

Activation of metabolite receptor GPR91 promotes platelet aggregation and transcellular biosynthesis of leukotriene C₄

Xiao Tang¹  | David Fuchs¹ | Shuai Tan² | Mette Trauelsen³ | Thue W. Schwartz³ | Craig E. Wheelock¹ | Nailin Li² | Jesper Z. Haeggström¹ 

¹Division of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

²Department of Medicine-Solna, Clinical Epidemiology Unit, Clinical Pharmacology Group, Karolinska Institutet, Stockholm, Sweden

³Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark

Correspondence

Jesper Z. Haeggström, Division of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.
Email: jesper.haeggstrom@ki.se

Funding information

Swedish Research Council, Grant/Award Number: 10350 and 2016-02798; Novo Nordisk Foundation, Grant/Award Number: NNF15CC0018346 and NNF10CC1016515

Abstract

Background: Succinate is a Krebs cycle intermediate whose formation is enhanced under metabolic stress, and for which a selective sensor GPR91 has been identified on various cell types including platelets. Platelet-derived eicosanoids play pivotal roles in platelet activation/aggregation, which is key to thrombus formation and progression of atherothrombosis.

Objectives: This study aims to decipher the molecular mechanism(s) and potential involvement of eicosanoids in succinate enhanced platelet activation/aggregation.

Methods: We used liquid chromatography-mass spectrometry (LC-MS)/MS-based lipid mediator profiling to identify eicosanoids regulated by succinate. We ran light transmittance aggregometry and flow cytometry to assess platelet aggregation, P-selectin expression, and platelet-polymorphonuclear leukocyte (PMN) adherence. Various pharmacological tools were used to assess the contributions of GPR91 signalling and eicosanoids in platelet aggregation.

Results: Succinate and two types of synthetic non-metabolite GPR91 agonists—*cis*-epoxysuccinate (cES) and Cmpd131—potentiated platelet aggregation, which was partially blocked by a selective GPR91 antagonist XT1. GPR91 activation increased production of 12-hydroxy-eicosatetraenoic acid (12-HETE), thromboxane (TX) A₂, and 12-hydroxyheptadecatrienoic acid (12-HHT) in human platelets, associated with phosphorylation of cytosolic phospholipase A₂ (cPLA₂), suggesting increased availability of free arachidonic acid. Blocking 12-HETE and TXA₂ synthesis, or antagonism of the TXA₂ receptor, significantly reduced platelet aggregation enhanced by GPR91 signalling. Moreover, platelet-PMN suspensions challenged with succinate exhibited enhanced transcellular biosynthesis of leukotriene C₄ (LTC₄), a powerful proinflammatory vascular spasmogen.

Conclusion: Succinate signals through GPR91 to promote biosynthesis of eicosanoids, which contribute to platelet aggregation/activation and potentially vascular inflammation. Hence, GPR91 may be a suitable target for pharmacological intervention in atherothrombotic conditions.

Manuscript handled by: Wolfgang Bergmeier

Final decision: Wolfgang Bergmeier, 7 January 2020

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2020 The Authors. *Journal of Thrombosis and Haemostasis* published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis

KEY WORDS

antiplatelet therapy, eicosanoids, GPR91, platelet aggregation, succinate

1 | INTRODUCTION

GPR91 (Sucnr1), a sensor of extracellular succinate, is expressed in immune, metabolic, and cardiovascular systems.¹ This receptor is closely related to purinergic receptors, in particular P2Y₁, and has been strongly implicated in pathogenic processes such as hypertension, ischemic tissue injury, diabetes, and immune responses.^{2,3} Platelets play crucial roles in hemostasis, and their activation and aggregation are essential for early clot formation at sites of vascular injury.⁴ In addition, platelets participate in immune responses together with leukocytes, and are recognized as critical players in inflammatory processes.^{5,6}

Eicosanoids are a series of oxygenated metabolites of arachidonic acid (AA) with potent actions in hemostasis and inflammatory responses.^{7,8} Biosynthesis of eicosanoids begins with the release of free AA from membrane phospholipids catalyzed by cytosolic phospholipase A₂ (cPLA₂). Further metabolism of AA is mainly directed by two types of oxygenases, cyclooxygenases (COX-1 and COX-2) and lipoxygenases (5-, 12-, and 15-LOX), leading to the generation of prostaglandins, thromboxanes, hydroxy and dihydroxy fatty acids, including the leukotrienes, via enzymes in downstream pathways. Upon activation, platelets rapidly liberate AA by phosphorylated and activated cPLA₂ (p-cPLA₂) for eicosanoid synthesis. The major platelet-derived eicosanoids are 12-hydroxy-eicosatetraenoic acid (12-HETE), generated by platelet 12-LOX, and TXA₂ together with equimolar amounts of 12-hydroxy-heptadecatrienoic acid (12-HHT), in a reaction catalyzed by TX synthase.^{9,10} Platelets also participate in synthesis of other eicosanoids, especially leukotriene C₄ (LTC₄), via transcellular metabolism of LTA₄ generated along the 5-LOX pathway by neighboring activated leukocytes.^{6,11}

Previous work has demonstrated that succinate can potentiate platelet activation.^{12,13} Here, we sought to elucidate the molecular mechanism(s) and potential involvement of eicosanoids in this prothrombotic effect using liquid chromatography-mass spectrometry (LC-MS)/MS based lipid mediator profiling, recently identified synthetic GPR91 agonists and antagonists, as well as inhibitors of key enzymes in the eicosanoid cascade. We report a critical role of GPR91 in this response as well as the ability of this metabolite receptor to promote transcellular generation of pro-inflammatory LTC₄.

2 | MATERIALS AND METHODS

2.1 | Reagents

Succinate (sodium succinate dibasic hexahydrate), adenosine 5'-diphosphate (ADP), forskolin, and monoclonal antibody against human

Essentials

- GPR91 is expressed on platelets and can sense extracellular succinate.
- Succinate enhances platelet aggregation, and release of 12-HETE, TXA₂, and 12-HHT via GPR91 signaling.
- Succinate-GPR91 activation enhances transcellular biosynthesis of LTC₄ in platelet PMN suspension.
- GPR91 is a potential target for development of antiplatelet agents.

β-actin were purchased from Sigma-Aldrich. Polyclonal antibody against GPR91 was from Abcam, while p-ERK, ERK, p-cPLA₂, cPLA₂, COX-1 and COX-2 antibodies were from Cell Signaling Technology. Fluorescence-labeled antibodies against P-selectin, CD42a and CD45 were from Becton Dickinson. cES and Cmpd131 were custom synthesized by Enamine, Kiev, Ukraine and compound XT1 by Ramidus AB (Ideon Science Park). ML355, SC-560, acetylsalicylic acid (ASA), SQ29.548, and oxylipin standards were from Cayman Chemical.

2.2 | Blood collection and platelet preparation

For LC-MS/MS analysis, blood was collected from healthy volunteers with BD Vacutainer[®] ACD-A tubes, while for platelet light transmittance aggregometry (LTA) BD Vacutainer[®] citrate tubes were used. All volunteers gave informed consent to donate blood (approved by the Ethics Committee of Karolinska Institutet Dnr 94-146) and denied intake of non-steroidal anti-inflammatory drugs for the past 14 days. The whole blood samples were centrifuged at 190 g for 10 minutes, and the upper two thirds of platelet rich plasma (PRP) was collected. Further centrifugation at 1400 g for 10 minutes yielded platelet poor plasma (PPP).

2.3 | Polymorphonuclear isolation and platelet/PMN co-culture

Human polymorphonuclear (PMN)s were isolated by dextran sedimentation and Ficoll-Paque Premium (GE Healthcare Bio-Sciences) gradient centrifugation, followed by hypotonic lysis of erythrocytes, yielding a purity of >99% PMNs and >96% neutrophils. PMNs were resuspended in phosphate buffered saline (PBS) to 2×10^7 cells/mL and co-incubated with PRP (1:9, v/v) in the presence of various compounds at 37°C for indicated times. Incubations were stopped with

two volumes of methanol and soluble extracts collected for LC-MS/MS analysis.

2.4 | Eicosanoid extraction and analysis by LC-MS/MS

Samples were diluted 1:1 with extraction buffer (pH = 5.6) and deuterated internal standards were added prior to solid phase extraction (SPE). Compounds were eluted with 2.5 mL of methanol and evaporated under N₂ gas (TurboVap LV; Biotage). Extracts were reconstituted to a final volume of 70 μ L in methanol/water (6:1, v/v) and filtered using membrane spin filters (0.3 μ mol/L; Merck Millipore Cooperation). Extracted samples and calibration standards were analyzed on a Acquity UPLC separation module coupled to a Xevo-TQXS triple quadrupole mass spectrometer (Waters Corp.) as previously described.¹⁴

2.5 | Light transmittance aggregometry

Light transmittance aggregometry analysis was performed on a four-channel aggregometer (PAP-4; Bio-Data Corporation). PRP samples were pre-incubated with vehicle or various inhibitors/antagonists at 37°C. ADP (1 μ mol/L) was added with or without GPR91 agonists, and the platelet aggregation was recorded for 8 minutes. The magnitude of final aggregation was analyzed.

2.6 | Flow cytometry

Whole blood samples were incubated with various compounds and fluorescence-labeled antibodies for 20 minutes, fixed with 0.5% paraformaldehyde (PFA) and subjected to flow cytometric analysis of P-selectin surface expression and platelet-PMN aggregates as previously described.^{15,16}

2.7 | Western blot

Pelleted platelets were lysed with radioimmunoprecipitation assay (RIPA) buffer and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and subsequent protein transfer using an iBlot® 2 system (Thermo Fisher). Protein bands were visualized with enhanced chemiluminescence detection (Thermo Fisher).

2.8 | Statistics

All data are presented as mean \pm standard error of mean (SEM). Differences among groups were assessed by one-way, two-way

analysis of variance (ANOVA) or Student's *t*-test and a value of *P* < .05 was considered statistically significant.

3 | RESULTS AND DISCUSSION

3.1 | GPR91 signaling enhances ADP-mediated platelet activation and aggregation

Robust expression of GPR91 in platelets was detected by western blot analysis (Figure 1A). We then challenged PRP with ADP together with succinate or any of two synthetic non-metabolite agonists of GPR91, namely cES or Cmpd131. While cES is a conformationally constrained succinate analog, Cmpd131 is a larger backbone modified analog with an amide-linked hydrophobic "side chain," which fits into a side pocket of GPR91.^{17,18} Succinate, the endogenous receptor ligand, and the two synthetic agonists all enhanced ADP-induced platelet aggregation (Figure 1). We also synthesized a potent and selective antagonist of GPR91, here denoted XT1, according to a previously published synthetic strategy (Compound 4c in¹⁹). Pre-incubation with XT1 partially inhibited the effect of succinate lending further support to the notion that GPR91 plays an essential role in this response (Figure 1E).

3.2 | GPR91 agonists elicit 12-HETE, TXA₂, and 12-HHT production from human platelets

In search of lipid mediators that could be involved in succinate-enhanced platelet aggregation, we directly assessed the formation of oxygenated derivatives of polyunsaturated fatty acids (AA, EPA, DHA, and LA) in PRP upon GPR91 activation by LC-MS/MS quantification. Within the panel of analytes, 46 lipid species were detected, with only six AA derivatives (for which the biosynthetic routes are depicted in Figure 2A) influenced by succinate challenge (Figure 2B). By far the most abundant eicosanoids produced by platelets challenged with 1 mmol/L succinate were 12-HETE, TXA₂, and 12-HHT (Figure 2C). Minor amounts of PGD₂, PGE₂, and PGF_{2 α} were also detected, probably reflecting COX-1 activity. Similar effects were observed for cES (Figure 2C,D), with a more efficient induction of 12-HETE from platelets by cES than succinate. Succinate and cES increased the phosphorylation of cPLA₂ and ERK but not p38 MAPK (Figure 2E), which translates to increased liberation of AA from phospholipids and more substrate for eicosanoid generation.²⁰ As expected, COX-1 protein level was not influenced by succinate or cES treatments (Figure 2E), and there was no detectable COX-2 protein in any of the treatment groups. Furthermore, succinate potentiated TXA₂ production in ADP-challenged platelets, and pre-incubation with 1 μ mol/L XT1, significantly inhibited this effect (Figure 2F). Together, these results indicate that GPR91 ligation primarily leads to activation of ERK and cPLA₂, which in




FIGURE 1 GPR91 activation potentiates platelet aggregation. A, Western blot analysis of GPR91 and Beta-actin expression in human monocyte-derived macrophage (Mac), platelet (Plt), and polymorphonuclear (PMN), with band intensity of GPR91 normalized by Beta-actin as indication of GPR91 expression ($n = 3$). B-D, Vehicle, 1 mmol/L succinate, 1 mmol/L cES, or 100 μ mol/L Cmpd131 was added with or without 1 μ mol/L adenosine 5'-diphosphate (ADP) and aggregation assessed with the light transmittance aggregometry (LTA) assay ($n = 4$). E, Platelets were pre-incubated with vehicle or 1 μ mol/L XT1 for 1 hour, followed by succinate or cES added with ADP to assess the aggregation magnitude of platelets ($n = 3$). * $P < .05$, ** $P < .01$

turn promotes eicosanoid biosynthesis from human platelets via COX and LOX pathways.

3.3 | Targeting 12-LOX, COX, and TP receptor ameliorate GPR91-potentiated platelet activation

As 12-HETE was one of the major eicosanoids triggered by GPR91 ligation (Figure 2B), a 12-LOX inhibitor-ML355 was used to assess the role of 12-LOX products (12-HpETE and 12-HETE) in succinate-potentiated aggregation induced by ADP. Pre-incubation with ML355 significantly inhibited this succinate potentiation (Figure 3A), suggesting an involvement of 12-LOX. Inhibition of platelet COX-1 by ASA or the selective inhibitor SC-560 also reduced succinate-enhanced platelet aggregation (Figure 3B,C) as did the TP receptor antagonist SQ29.548 (Figure 3D). Moreover, the combination of ML355 with ASA, SC-560, or SQ29.548 showed a more effective inhibitory effect on platelet aggregation than did any of the agents

alone. These results suggest that 12-LOX product(s) and TXA₂ are involved in GPR91 potentiated platelet aggregation induced by ADP (Figure 3). Succinate also promoted formation of 12-HHT, a side product of TXA₂ biosynthesis (Figure 2). This compound is the high-affinity ligand of the BLT2 receptor²¹ and may elicit responses in neighboring leukocytes. However, it should be noted that the role of BLT2 in cells of the vascular system is poorly understood.

3.4 | Succinate-GPR91 activation enhances platelet-dependent conversion of neutrophil-derived LTA₄ to LTC₄

Platelets not only produce eicosanoids by themselves, but can also cooperate with neighboring cells to produce lipid mediators through transcellular metabolism.²² Because it has been reported that succinate can increase platelet surface expression of P-selectin, we asked whether this effect would be sufficient to promote transcellular




FIGURE 2 Activation of GPR91 triggers 12-hydroxy-eicosatetraenoic acid (12-HETE), thromboxane A₂ (TXA₂), and 12-hydroxy-heptadecatrienoic acid (12-HHT) production from human platelets. A, Biosynthetic routes of eicosanoids from membrane phospholipids. B-D, Platelets were incubated with vehicle, 1 mmol/L succinate, 1 mmol/L cES, or 100 μmol/L Cmpd131 at 37°C for 30 minutes. The reaction was stopped by two volumes of methanol followed by lipid mediator extraction and quantification by liquid chromatography-mass spectrometry (LC-MS)/MS (n = 6). B, Red and orange dots: arachidonic acid (AA) derivatives influenced by succinate challenge. Blue dots: Other oxygenated derivatives of polyunsaturated fatty acids. C, Absolute levels of AA derivatives influenced by succinate or cES (n = 6). D, Comparison of 12-HETE, TXB₂, 12-HHT production from platelets challenged with succinate or cES (n = 6). E, Western blot analysis of total protein from platelets treated with succinate and cES at 37°C for 30 minutes (n = 3). F, Platelets were pre-incubated with vehicle or 1 μmol/L XT1 for 1 hour, followed by adenosine 5'-diphosphate (ADP) added with or without succinate for 30 minutes. TXB₂ level in supernatant was assessed by ELISA (n = 4). *P < .05, **P < .01, ***P < .001




FIGURE 3 TXA₂ and 12-LOX product(s) are involved in succinate-potentiated platelet aggregation. A-D, Platelets were incubated at 37°C for 5 minutes with vehicle or (A) 50 μmol/L ML355 (n = 4), (B) 50 μmol/L ASA with or without 50 μmol/L ML355 (n = 6), (C) 5 μmol/L SC-560 with or without 50 μmol/L ML355 (n = 4), and (D) 5 μmol/L SQ29.548 with or without 50 μmol/L ML355 (n = 4). Afterwards, aggregation was assessed following induction by 1 μmol/L adenosine 5'-diphosphate (ADP) and 1 mmol/L succinate. *P < .05, **P < .01, ***P < .001

biosynthetic processes. We chose mixed platelet-PMN suspensions for assessment of transcellular biosynthesis of leukocyte-derived LTC₄ into LTC₄¹¹ because there is a distinct partitioning of critical enzymes between platelets (recipient, containing LTC₄ synthase/LTC4S) and PMNs (donor, harboring 5-LOX for production of LTC₄).

In our hands, succinate as well as cES enhanced P-selectin surface expression in human platelets (Figure 4A,B), suggesting an involvement of GPR91 in platelet-neutrophil interactions. Furthermore, platelet PMN suspensions challenged with succinate indeed promoted LTC₄ production as determined by LC-MS/MS analysis (Figure 4C). In contrast, there was no change of LTB₄ or 5-HETE production in succinate treated suspensions (Figure 4D,E), suggesting neutrophils are not activated by succinate treatment. Also, whole blood supplied with succinate showed a higher level of platelet-PMN adherence (Figure 4G), in line with our observation of P-selectin surface expression and LTC₄ production in succinate-treated platelets and platelet PMN suspension.

Of note, when synthetic exogenous LTC₄ (10 μmol/L) was used as the substrate source, PRP incubated with succinate produced more LTC₄ than control (Figure 4F), suggesting succinate increases LTC4S activity in platelets. LTC4S is post-translationally regulated by

phosphorylation that reduces enzyme activity.²³ Therefore, one may speculate that succinate can activate a protein phosphatase acting on LTC4S resulting in enhanced enzyme activity. Further studies will be required to understand the mechanism underlying the effect of succinate on LTC4S activation.

3.5 | Therapeutic implications of succinate-GPR91-eicosanoid signaling

Our data add GPR91 to at least three previously identified levels at which pharmacological intervention could reduce platelet activation and aggregation (COX-1, the platelet TXA₂ receptor, and 12-LOX). Low-dose ASA targets COX and is widely used for this purpose, while thromboxane receptor antagonists have been developed without making it to clinical settings. 12-LOX and 12-HETE have been implicated in platelet functions and thrombus formation²⁴ and recently, ML355, a potent and selective 12-LOX inhibitor, was suggested to impair platelet reactivity and clotting.²⁵ In fact, as ASA could only partially inhibit succinate potentiated platelet aggregation¹² (Figure 3B), the effectiveness of ML355 in




FIGURE 4 Succinate promotes transcellular biosynthesis of leukotriene C₄ (LTC₄). A-B, Whole blood was incubated with various compounds in HEPES buffer with fluorescence labeled P-selectin antibody at room temperature for 20 minutes, the cells were then fixed with 0.5% paraformaldehyde (PFA) and analyzed by fluorescence-activated cell sorting (FACS). C-E, Platelets and platelet-polymorphonuclear leukocytes (PMNs) were cocultured with 1 mmol/L succinate at 37°C for 30 minutes. The reaction was stopped by two volumes of methanol and lipid mediators were analyzed by liquid chromatography-mass spectrometry (LC-MS)/MS. F, 10 μmol/L LTA₄ with or without 1 mmol/L succinate was added to platelets and incubated at 37°C for 30 minutes. The reaction was stopped by two volumes of methanol and the lipid mediators were analyzed by LC-MS/MS. G, Whole blood was incubated with various compounds in HEPES buffer with fluorescence labeled CD45 and CD42a antibodies at room temperature for 20 minutes, the cells were then fixed with 0.5% PFA and analyzed by FACS. *P < .05

the current study supports targeting 12-LOX as a potential new antiplatelet therapy, especially in patients with ASA resistance or intolerance.

Succinate activates platelets with increased surface exposure of P-selectin, which promotes formation of platelet-neutrophil aggregates^{6,26} and transcellular biosynthesis of LTC₄.²⁷ This cooperative action could be an important source of LTC₄ under certain circumstances as both cell types are fast-reacting components in inflammation, especially in aspirin-exacerbated respiratory disease.²⁸ In fact, this notion can be extended to atherosclerosis and associated cardiovascular diseases. For instance, the recruitment of neutrophils into atherosclerotic lesion is partially dependent on activated platelets, which further promotes early lesional development of atherosclerosis.²⁹ Another example is the vulnerable atherosclerotic plaque, which is prone to rupture and thrombus formation. Although the pathogenic mechanism(s) are not well understood it is believed to involve exposure of plaque lipids and immune cells, which in turn activates platelets leading to clotting, a scenario potentially involving transcellular biosynthesis of leukotrienes.

The autocrine and paracrine regulatory mechanism through which succinate acts as a ligand for GPR91 now introduces a novel possibility for interfering with platelet activation. Succinate is generated and excreted by many different cell types under metabolic stress including hypoxia.³⁰ Here we find that succinate promotes platelet activation and aggregation as well as transcellular biosynthesis of the pro-inflammatory LTC₄. Thus, LTC₄, the parent compound of the spasmogenic and immune regulatory cysteinyl-leukotrienes, could be formed when clotting platelets attach to inflammatory cells of, for example, the vulnerable plaque. It appears that GPR91 antagonists could be a novel means to block this process.

ACKNOWLEDGMENTS

The authors thank Prof. Mats Hamberg for valuable expert advice. This study was supported by the Swedish Research Council (Grants 10350, 2016-02798) and an immunometabolism grant NNF15CC0018346 from the Novo Nordisk Foundation to University of Copenhagen (TWS), Karolinska Institutet Stockholm (JZH), and Oxford University, UK. The NNF Center for Basic Metabolic Research is supported by an unconditional grant (NNF10CC1016515) from the Novo Nordisk Foundation to University of Copenhagen (TWS).

CONFLICTS OF INTEREST

The manuscript has been read and approved for submission to JTH™ by all authors. The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

X. Tang contributed to the study design, performed the experiments, analyzed the data, and wrote the manuscript. S. Tan and N. Li contributed to the experimental design and interpretations. M. Trauelsen and T.W. Schwartz provided expertise in GPR91 pharmacology. D. Fuchs and C.E. Wheelock performed lipidomics. J.Z. Haeggström designed the study, analyzed the data, and wrote the manuscript.

ORCID

Xiao Tang  <https://orcid.org/0000-0003-2918-7748>

Jesper Z. Haeggström  <https://orcid.org/0000-0002-1823-5153>

REFERENCES

1. He W, Miao FJ, Lin DC, et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. *Nature*. 2004;429(6988):188-193.
2. Tan JK, McKenzie C, Marino E, Macia L, Mackay CR. Metabolite-sensing G protein-coupled receptors-facilitators of diet-related immune regulation. *Annu Rev Immunol*. 2017;35:371-402.
3. Husted AS, Trauelsen M, Rudenko O, Hjorth SA, Schwartz TW. GPCR-mediated signaling of metabolites. *Cell Metab*. 2017;25(4):777-796.
4. Badimon L, Padro T, Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. *Eur Heart J Acute Cardiovasc Care*. 2012;1(1):60-74.
5. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. *Trends Immunol*. 2004;25(9):489-495.
6. Laidlaw TM, Boyce JA. Platelets in patients with aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol*. 2015;135(6):1407-1414; quiz 15.
7. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. *Science*. 2001;294(5548):1871-1875.
8. Haeggstrom JZ. Leukotriene biosynthetic enzymes as therapeutic targets. *J Clin Invest*. 2018;128(7):2680-2690.
9. Hamberg M, Samuelsson B. Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. *Proc Natl Acad Sci U S A*. 1974;71(9):3400-3404.
10. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. *Proc Natl Acad Sci U S A*. 1975;72(8):2994-2998.
11. Maclouf JA, Murphy RC. Transcellular metabolism of neutrophil-derived leukotriene A4 by human platelets. A potential cellular source of leukotriene C4. *J Biol Chem*. 1988;263(1):174-181.
12. Spath B, Hansen A, Bokemeyer C, Langer F. Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists. *Platelets*. 2012;23(1):60-68.
13. Macaulay IC, Tijssen MR, Thijssen-Timmer DC, et al. Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. *Blood*. 2007;109(8):3260-3269.
14. Kolmert J, Fauland A, Fuchs D, et al. Lipid mediator quantification in isolated human and guinea pig airways: an expanded approach for respiratory research. *Anal Chem*. 2018;90(17):10239-10248.
15. Li N, Wallen NH, Hjerdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. *Circulation*. 1999;100(13):1374-1379.
16. Li N, Goodall AH, Hjerdahl P. Efficient flow cytometric assay for platelet-leukocyte aggregates in whole blood using fluorescence signal triggering. *Cytometry*. 1999;35(2):154-161.
17. Trauelsen M, Rexen Ulven E, Hjorth SA, et al. Receptor structure-based discovery of non-metabolite agonists for the succinate receptor GPR91. *Mol Metab*. 2017;6(12):1585-1596.
18. Geubelle P, Gilissen J, Dilly S, et al. Identification and pharmacological characterization of succinate receptor agonists. *Br J Pharmacol*. 2017;174(9):796-808.
19. Bhuniya D, Umrani D, Dave B, et al. Discovery of a potent and selective small molecule hGPR91 antagonist. *Bioorg Med Chem Lett*. 2011;21(12):3596-3602.
20. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. *Cell*. 1993;72(2):269-278.

21. Okuno T, Iizuka Y, Okazaki H, Yokomizo T, Taguchi R, Shimizu T. 12(S)-Hydroxyheptadeca-5Z, 8E, 10E-trienoic acid is a natural ligand for leukotriene B4 receptor 2. *J Exp Med*. 2008;205(4):759-766.
22. Sala A, Folco G, Murphy RC. Transcellular biosynthesis of eicosanoids. *Pharmacol Rep*. 2010;62(3):503-510.
23. Ahmad S, Ytterberg AJ, Thulasingam M, et al. Phosphorylation of leukotriene C4 synthase at serine 36 impairs catalytic activity. *J Biol Chem*. 2016;291(35):18410-18418.
24. Tourdot BE, Holinstat M. Targeting 12-lipoxygenase as a potential novel antiplatelet therapy. *Trends Pharmacol Sci*. 2017;38(11):1006-1015.
25. Adili R, Tourdot BE, Mast K, et al. First selective 12-LOX inhibitor, ML355, impairs thrombus formation and vessel occlusion in vivo with minimal effects on hemostasis. *Arterioscler Thromb Vasc Biol*. 2017;37(10):1828-1839.
26. Li N, Goodall AH, Hjendahl P. A sensitive flow cytometric assay for circulating platelet-leucocyte aggregates. *Br J Haematol*. 1997;99(4):808-816.
27. Maugeri N, Evangelista V, Celardo A, et al. Polymorphonuclear leukocyte-platelet interaction: role of P-selectin in thromboxane B2 and leukotriene C4 cooperative synthesis. *Thromb Haemost*. 1994;72(3):450-456.
28. Laidlaw TM, Kidder MS, Bhattacharyya N, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. *Blood*. 2012;119(16):3790-3798.
29. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. *Circulation*. 2010;122(18):1837-1845.
30. Tretter L, Patocs A, Chinopoulos C. Succinate, an intermediate in metabolism, signal transduction, ROS, hypoxia, and tumorigenesis. *Biochem Biophys Acta*. 2016;1857(8):1086-1101.

How to cite this article: Tang X, Fuchs D, Tan S, et al.

Activation of metabolite receptor GPR91 promotes platelet aggregation and transcellular biosynthesis of leukotriene C₄. *J Thromb Haemost*. 2020;18:976-984. <https://doi.org/10.1111/jth.14734>